Proteasome inhibitors in the treatment of multiple myeloma

Area of Science:

• Oncology
• Pharmacology

Background:

• Proteasome inhibition is a validated therapeutic strategy for multiple myeloma.
• Bortezomib, the first-in-class proteasome inhibitor, demonstrates significant clinical activity.
• Carfilzomib, a second-generation inhibitor, is approved for relapsed/refractory multiple myeloma.

Purpose of the Study:

• To provide a comprehensive review of proteasome inhibitors in multiple myeloma treatment.
• To compare the pharmacology, administration, efficacy, and safety of existing and investigational agents.
• To evaluate the potential of novel proteasome inhibitors for future myeloma therapy.

Main Methods:

• Literature review of clinical trials and scientific publications.
• Comparative analysis of bortezomib, carfilzomib, and investigational agents (MLN9708, marizomib, oprozomib, delanzomib).
• Evaluation of pharmacological properties, routes of administration, efficacy, and safety profiles.

Main Results:

• Proteasome inhibitors play a crucial role in the multiple myeloma treatment pathway.
• Key differences and similarities exist among bortezomib, carfilzomib, and investigational agents regarding their profiles.
• Investigational agents show promise in preclinical and early clinical development.

Conclusions:

• Proteasome inhibitors represent a cornerstone in multiple myeloma management.
• Understanding the nuances of different agents is vital for optimizing treatment strategies.
• Continued development of novel proteasome inhibitors holds potential for advancing multiple myeloma care.